RheumNow's expanded coverage of the #ACR2019 annual meeting is sponsored in part by Horizon Therapeutics. All content chosen by RheumNow and its faculty.

Phase 2b Bimekizumab study results in PsA shows neutralizing IL 17F and IL 17A may be a new target for LDA/treatment. https://t.co/uHvkFJn5z7 #ACR19 @RheumNow abs#2881 https://t.co/2EfzmyxY4M

• Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Acti…

Rilonacept may have a role in Tx of steroid-refractory recurrent idiopathic pericarditis abstr#2905 #ACR19 #cleclinicrheum @RheumNow @CleClinicMD

Risankizumab (RZB), humanized IgG1 monoclonal antibody and selective IL23p19 inhibitor, superior to PBO in PsA. Initial phase 2 results. No new safety signals noted. https://t.co/Jv1zpcg5Zd #ACR19 @RheumNow abs#2877

• Safety and Efficacy Results from the Open Label Extension of a Phase 2 Trial of…

Infections In out patients are increased as measured by antimicromial scripts with RA and TNFi use comparing popn controls and pre and post RA TNFi use in pan Iceland registry #ACR19 #ACR @RheumNow abstr 2873. Higher than controls pre &even more after TNFi https://t.co/SlkIPP9WsJ

A new MBDA-based CVD risk score looks promising, for accurately predicting CVD risk in RA pts, abstr#2350 @RheumNow #ACR19

Do you think of cachexia in SLE? I didn't before this. Maybe I missed what it is as 50% of Hopkins lupus cohort have cachexia by 5 yrs. Mot my experience #ACR #ACR19 @RheumNow #SLE abstract 1567 https://t.co/7cAU9r7RJV

Continue or stop biologics for RA if pregnant? Abstr# 2292 and 2279 show increase in flares, GC use, if biologics stopped at time of positive pregnancy test @RheumNow #ACR19

Icelandic study shows RA pts use more antimicrobials in the 2 yrs prior to TNFi tx and have increased use 2 yrs after tx. https://t.co/GyUdQT2NvD abs#2873 #ACR19 @RheumNow https://t.co/HKU2IOPwcw

• Antimicrobial Use Is High in Patients with Rheumatoid Arthritis, and Further In…

Tofa is not different from bDMARDs in Corrona for cancer and deaths. reassuring and adds to growing safety data #ACR #ACR19 @RheumNow abstr 2874 https://t.co/pLVAkQ7UR6

Quote of the day “The absence of crackles is not the absence of ILD in systemic sclerosis” by Saketkoo LA in SSc. Also think of other causes of dyspnoea and cough in SSc #ACR19 @RheumNow https://t.co/po2XG9hnYY

RA patients failing either UPA or adalimumab may benefit from switching to the other therapy abstr#2907 #ACR19 @RheumNow

Go-DACT proof on concept results: golimumab + MTX superior to monotherapy MTX in PsA dactylitis. https://t.co/dEGnjiuGZf #ACR19 @RheumNow abs#2876

• Go-Dact: A Phase 3b Randomized Double-Blind Placebo-Controled Proof-Of-Concept …

Can paired synovial MCP biopsies in ERA predict damage? Nice study shows Bcell rich biopsy that is perstistent. This may eventually help with Rx and prognosis #ACR19 #ACR @RheumNow abstract 2870 https://t.co/oQTgiTOtEX

#ACR19 Abst#2877: Open Label Extension of a Phase 2 for risankizumab (IL23i) for PsA Effect seems to stick around and favorable safety profile @RheumNow https://t.co/pFn0q61exs